Giuseppe Astarita, Ph.D. — Extended CV

Professional Summary

Translational scientist with 20+ years of experience at the intersection of neuroscience, metabolic disorders, inflammation, and rare disease, with deep expertise in biomarker discovery and development powered by multi-omics approaches. Recognized for leveraging cutting-edge technologies to translate biomarkers into clinical applications, supported by a robust portfolio of 90+ peer-reviewed publications, 13,000+ citations, h-index 54, and 16 granted patents.

Platform expertise spans multi-omics mass spectrometry (lipidomics, metabolomics, and proteomics) alongside immunoassay technologies (Olink, SomaLogic) and fit-for-purpose assay development. Adept at driving scientific innovation, fostering collaborations with key opinion leaders and CROs, and advancing drug programs from preclinical through clinical stages — with a consistent track record of turning data into decisions.

Serial platform builder: established and led multi-omics biomarker laboratories and teams across academic institutions (UC Irvine, Georgetown, IIT), industry (Denali, Arkuda), and through consulting for multiple startups — from instrument acquisition and assay development to full scientific programs.
Publication and intellectual property record: 90+ peer-reviewed publications, h-index 54, 16 granted patents, and editor of a Springer book on Ion Mobility-Mass Spectrometry and two IJMS special issues — reflecting sustained scientific leadership and innovation.
Clinical-stage leadership: MOA, pharmacodynamic, and patient stratification endpoints embedded in clinical protocols and regulatory submissions across neuroscience, metabolic, and rare disease.
Consulting practice serving 20+ biotech and pharma clients: translational strategy, IND-enabling programs, and multi-omics integration from early discovery through clinical development.
Scientific depth: lysosomal biology (progranulin, GBA-pathway lipids, ceramide/sphingolipid metabolism, LRRK2-associated mechanisms), endocannabinoid signaling, lipid mediators, and omega-3 fatty acid biology (DHA/EPA metabolism in brain and neurodegeneration; EPA-derived specialized pro-resolving mediators — resolvins, protectins, maresins — in inflammation resolution) — directly applied to neurodegeneration, rare disease, and inflammatory programs.
Pioneered innovative mass spectrometry approaches for lipidomics and metabolomics — including ion mobility MS, novel lipid separation columns, and new software tools — advancing the field's analytical capabilities and contributing to 12+ patents and 20+ publications at Waters Corporation and beyond.
AI & computational biomarker discovery: leveraged machine learning and statistical integration of large public multi-omics resources (PPMI, AMP‑PD, UK Biobank, EPIC, Knight-ADRC) alongside in-house lipidomics/proteomics datasets to identify disease-relevant signatures, stratify molecular subtypes, and prioritize translational biomarkers for clinical development.

Most Significant Contributions

Six thematic areas summarize the focus of my scientific contributions. The biomarker discovery methods and platforms I developed — spanning lipids, metabolites, and proteins — have served as a foundation for studies of health and disease, and have been adopted by international laboratories, biotech, and pharma. Reflected in 90+ peer-reviewed publications, 13,000+ citations, h-index 54, and 16 granted patents.

Translational integration of multi-omics in matrixed biopharma organizations. Established and led high-throughput lipidomics and metabolomics platforms across multiple matrixed biotech and pharma settings (Denali, Arkuda, Metabolon, Waters, IIT) — embedding multi-omics readouts across discovery, translational, and clinical-stage programs to support biomarker strategy, target engagement, mechanism-of-action studies, and patient stratification. This integrative perspective is captured in the lead-author review Astarita, Kelly & Lasky-Su, “Metabolomics and lipidomics strategies in modern drug discovery and development” (Drug Discov Today 2023), which frames how metabolomics/lipidomics accelerate decision-making across the drug-development pipeline.
Analytical approaches for identifying biomarkers. Pioneered untargeted lipidomics and metabolomics methods built on hyphenated mass spectrometry — most notably ion mobility-MS — for the discovery of novel molecular species and biochemical pathways. Senior-author work in Mass Spectrometry Reviews (Paglia, Smith & Astarita 2021), Nature Protocols (Paglia & Astarita 2017), and Analytical Chemistry (Paglia et al. 2015) established collision-cross-section measurement as a routine fingerprint for molecular identification, and the methods have been adopted across academic and industry laboratories. Underlying inventions captured in 8+ technology and software patents — including ion mobility/quadrupole MS instrumentation, CCS-fragment chemical class identification, chemical tagging for ID/quantification/spatial localization, isotopically labeled analyte structural elucidation, and metabolic-pathway/metabolite identification methods.
Analytical approaches for quantifying biomarkers. Developed targeted lipidomics, metabolomics, and proteomics workflows for biomarker quantification in biological samples — including endocannabinoid profiling (Astarita, Geaga, Ahmed & Piomelli, Int Rev Neurobiol 2009), oxylipin/eicosanoid panels for polyunsaturated-fatty-acid metabolites (Astarita, Kendall, Dennis & Nicolaou, BBA Lipids 2015), and high-throughput LC-MS/MS quantification of glycosaminoglycans as biomarkers of mucopolysaccharidosis II (Wang et al., IJMS 2020). Quantification methods underpin patents on lysosomal storage disorder biomarkers and essential-nutrient ratio determination, providing the analytical foundation for translational and clinical biomarker programs.
Biomarkers in nutrition and toxicology. Identified molecular biomarkers of inflammatory and apoptotic processes modifiable by nutritional and pharmacological interventions, including a protective omega-6/omega-3 lipidomic signature in fat-1 transgenic mice (Astarita et al., PLoS ONE 2014), serum lipid mediator responses to ionizing radiation that informed radiation-injury biosignature work (Laiakis et al., J Proteome Res 2014, 2017), de novo ceramide biosynthesis as a driver of methamphetamine-induced cellular senescence (Astarita et al., PLoS ONE 2015), and an emerging role for metabolomics in nutrition science (Astarita & Langridge, Lifestyle Genomics 2013). Patents in this domain cover omega-3-based DHA brain delivery for cognitive dysfunction, ceramide-pathway treatment of methamphetamine toxicity, and ambient-ionization MS for radiation-exposure monitoring.
Biomarkers in neuroscience and metabolic disorders. Contributed to the discovery of lipid, metabolite, and protein biomarkers in cognitive impairment, neurodegeneration, and metabolic disease — including an Aβ42-dependent anandamide deficit in Alzheimer's (Jung & Astarita et al., Neurobiol Aging 2011), elevated brain stearoyl-CoA desaturase in Alzheimer's (Astarita et al., PLoS ONE 2011), peroxisomal dysfunction in DHA metabolism linking liver and brain (Astarita et al., PLoS ONE 2010; Astarita & Piomelli, Prostaglandins Leukot Essent Fatty Acids 2011), unbiased metabolomic dysregulation of mitochondrial aspartate metabolism in the AD brain (Paglia et al., J Proteome Res 2016), and metabolomic markers of LRRK2-status-independent kynurenine and polyamine pathways in Parkinson's disease (Crotty et al., Neurology 2020). Patents include lipidomic biomarkers for Alzheimer's disease, DHA delivery to the brain for cognitive dysfunction, and methods for treating dysregulated lipid metabolism.
Functional roles of biomarkers in cell biology and physiology. Integrated lipidomics, metabolomics, and proteomics with imaging, microscopy, and FACS to characterize the biology of organelles such as lysosomes and lipid droplets — contributing to high-impact translational publications including brain delivery of a lysosomal enzyme via a BBB transport vehicle (Ullman et al., Sci Transl Med 2020), TREM2 regulation of microglial cholesterol metabolism (Nugent et al., Neuron 2020), Alzheimer's-associated PLCγ2 as a TREM2/inflammation signaling node (Andreone et al., Nat Neurosci 2020), and rescue of a lysosomal storage disorder by a brain-penetrant progranulin biologic (Logan et al., Cell 2021). Co-inventor on the corresponding patents covering lysosomal storage disorder biomarkers, progranulin-associated disorder methods, and BBB-penetrant enzyme replacement therapy fusion proteins.

Relevant Experience

Principal Consultant — Biomarker & Omics Strategy08/2020 – Present

MyMetabolome Consulting · Belmont, MA

Advised 20+ biotech and pharmaceutical clients on translational biomarker strategy, supporting IND-enabling programs, clinical biomarker frameworks, and multi-omics integration across neuroscience, metabolic, and rare disease indications.
Selected engagements:
- Academic partner (2026) — leading multi-omics data analysis and biological interpretation for a translational research program, generating insights for downstream publication and grant submissions.
- Boston-area startups — laboratory build-out (2021–2026) — long-running advisory work guiding multi-omics laboratory setup, instrumentation selection, and recruitment of expert scientific teams for early-stage biotech ventures.
- Multi-omics services startup (2025) — advised on multi-omics integration strategy and commercial positioning for biotech and pharma clients spanning discovery and translational programs.
- Analytical-services startup (2024) — established laboratory SOPs, instrumentation roadmap, and high-throughput mass spectrometry workflows for routine customer-facing analytical services.
- Boston-area neurodegeneration biotech (2023–2024) — designed biomarker panel strategy for a clinical-stage program; defined fluid biomarker selection, assay readiness criteria, and translational endpoints.
- Microbiome-focused startup (2021–2022) — analyzed and presented microbiome multi-omics datasets; findings contributed to patent applications.
- Large pharmaceutical company (2021–2022) — advised on assay development for biomarkers and enzymatic activity measurements in CSF and plasma matrices to support translational and clinical-stage programs.
Built multi-omics laboratory capabilities and teams for clients from the ground up — including platform selection, instrument acquisition, assay development, and SOP development for mass spectrometry-based analytical labs.
Provided end-to-end scientific leadership across experimental design, data analysis and interpretation, and strategic planning for multi-omics biomarker programs.
Identified and characterized biomarkers contributing to patent applications, peer-reviewed publications, and the advancement of proof-of-concept, exploratory, and clinical programs.
Supported grant applications and manuscripts through experimental strategy, biomarker rationale, and data interpretation; advised on core-facility-style workflows including method standardization and QC practices.
Industry talks at Denali, Metabolon, and Arkuda Scientific Advisory Boards (2017–2023) and client engagements at 20+ biopharma organizations through MyMetabolome (2020–present); details available on request.

Adjunct Assistant Professor, Biochemistry & Molecular Biology02/2012 – Present

Georgetown University · Washington, DC

Pioneered lipidomics capabilities at the Lombardi Cancer Center, enhancing the institution's biomarker research in neurodegeneration, inflammation, and cancer.
Co-authored 40+ peer-reviewed manuscripts and book chapters spanning lipidomics, metabolomics, and translational neuroscience; recipient of the New Investigator Research Grant NIRG-11-203674 from the Alzheimer's Association.
Mentored undergraduate and graduate students; teach graduate-level course BCHB-596 Clinical Metabolomics — covering lipidomics, biomarker science, translational applications, and emerging technologies for biomarker discovery.
Serve on Ph.D. thesis committees, providing scientific guidance and evaluation for doctoral candidates in biochemistry and related disciplines.

Senior Director, Biomarker Discovery04/2022 – 10/2023

Arkuda Therapeutics · Watertown, MA

Led end-to-end biomarker strategy for clinical-stage programs targeting lysosomal dysfunction, neuroinflammation, and neuronal health — defining MOA, pharmacodynamic, and patient stratification endpoints using multi-omics and CSF/plasma biomarker panels.
Identified disease-relevant biomarkers supporting indication expansion and exploration of new therapeutic areas; discovered markers of pathway engagement offering mechanistic insights into drug efficacy.
Built and directed integrated multi-omics pipelines incorporating LC-MS/MS, Olink, and SomaLogic platforms for translational and clinical readouts.
Principal Investigator on a $350K two-year proposal to The Michael J. Fox Foundation Lysosomal Biomarkers Program (2023): designed a strategy to identify lipid- and protein-based lysosomal signatures for Parkinson's disease patient stratification by integrating in-house compound-treated NHP datasets with large public multi-omics resources (PPMI Projects 151/180/196, UK Biobank Pharma Proteomics Project, EPIC4ND, WashU Knight-ADRC) using machine learning and univariate analyses; assembled a cross-institution team including academic KOLs (Cruchaga, Lill) and CROs (Fios Genomics, QPS, Biomere).
Contributed to lysosomal biomarker work supported by an earlier MJFF grant to Arkuda (MJFF-020249), generating proteomics (SomaLogic) and lipidomics signatures of lysosomal pathway engagement (BMP, gangliosides, GRN, PSAP, cathepsins) in non-human primate plasma, urine, and CSF following compound treatment.
Functioned as the biomarker strategy lead within a fast-paced, matrixed startup organization, partnering closely with biology, pharmacology, and clinical teams to drive cross-functional alignment across FTD, Parkinson's, and lysosomal storage disorder programs.
Managed assay development and validation programs ensuring regulatory readiness; oversaw CRO partnerships delivering high-quality translational datasets for governance submissions.
Collaborated with external KOLs and published 2 peer-reviewed manuscripts; presented translational data at Scientific Advisory Board (SAB) meetings.

Senior Scientific Manager12/2020 – 03/2022

Metabolon · San Francisco, CA

Reimagined the strategy for omics-based biomarker analysis, pioneering the development and implementation of 20+ biomarker panels across diverse diseases and biochemical pathways — including neurodegeneration, inflammation, microbiome, aging, oncology, and metabolic disorders — advancing a panel-based multi-omics approach to translational and clinical applications.
Implemented strategic solutions for microbiome and multi-omics studies, functioning as scientific and technical liaison communicating complex content to diverse audiences across pharma, biotech, and academia.
Orchestrated scientific publications strategy and presented 5+ webinars and publications, ensuring impactful dissemination of research findings across 20+ pharmaceutical, biotech, and academic clients.

Principal Scientist, Head of Omics Mass Spectrometry12/2018 – 07/2020

Denali Therapeutics · South San Francisco, CA

Founded and scaled the omics mass spectrometry function at a newly launched biotech — built from the ground up into a centralized multi-omics platform supporting 20+ programs across the full development pipeline.
Led biomarker strategy advancing 6+ drug development programs to Phase 1/2, defining pharmacodynamic endpoints and patient stratification criteria adopted in clinical protocols.
Contributed to the development of a CSF heparan sulfate surrogate endpoint incorporated into a regulatory approval — a concrete example of how rigorous biomarker science translates into clinical and regulatory impact.
Coordinated multi-omics analysis across 20+ Denali programs (exploratory and pipeline), overseeing experimental design and analysis of 10,000+ biological samples.
Led large-scale multi-omics analysis (lipidomics, metabolomics, and proteomics) of 350+ CSF, plasma, and urine samples from sporadic and LRRK2+ Parkinson's disease patients as part of the MJFF LRRK2 Cohort Consortium; dataset deposited in the public Consortium database and contributing to multiple publications.
Contributed to grant proposals supporting Denali's Parkinson's disease research, including applications to The Michael J. Fox Foundation and the LRRK2 Cohort Consortium — providing biomarker rationale, multi-omics experimental strategy, and translational endpoint design.
Operated in a fast-paced, matrixed organization, partnering closely with clinical, regulatory, discovery, and bioinformatics teams; led a team of 6+ scientists supporting multi-omics biomarker strategy across programs.
Co-authored 8+ high-impact publications and co-invented 6 patents in translational neuroscience and rare disease.

Senior Scientist, Head of Omics Mass Spectrometry08/2016 – 11/2018

Denali Therapeutics · South San Francisco, CA

Established infrastructure, workflows, and scientific direction for lipidomics, metabolomics, and proteomics from the ground up; championed integration of omics-based approaches across all development phases.
Advocated for emerging technology adoption and implemented risk mitigation frameworks for biomarker studies across early-stage programs.
Promoted to Principal Scientist in recognition of scientific leadership and program impact.

Principal Scientist & Global Business Development Manager, Omics09/2011 – 07/2016

Waters Corporation · Milford, MA

Managed worldwide programs for metabolomics and lipidomics, overseeing application development, new technology deployment, and 100+ scientific and business collaborations with KOLs across academia, pharma, and industry.
Pioneered innovative mass spectrometry approaches for lipidomics and metabolomics, including ion mobility MS, novel lipid separation columns, and new computational tools — contributing to 12+ patents and 20+ publications.
Contributed to specification, development, and testing of new software tools for lipidomic and metabolomic data processing and annotation.
Organized and led scientific events, workshops, and educational and training sessions globally, elevating awareness of metabolomics and lipidomics across the life sciences and biopharma communities.
Maintained in-depth competitive intelligence across the multi-omics and biomarker technology landscape, informing strategic positioning and identifying emerging opportunities.
Co-invented 12+ patents and authored 20+ peer-reviewed publications alongside 40+ application notes, webinars, and technical communications.
Presented at 100+ scientific conferences; delivered 20+ invited oral communications internationally across pharma, academia, and nutrition sectors.
Led development of metabolomics approaches using ion mobility mass spectrometry; served as scientific and technical liaison communicating complex content to diverse audiences.

Team Leader, Drug Discovery & Development2008 – 09/2011

Italian Institute of Technology · Genoa, Italy

Led lipid biomarker programs for neurodegenerative, metabolic, and inflammatory disorders; established mass spectrometry facility from the ground up in a newly launched research institute.
Directed multidisciplinary teams and delivered drug discovery milestones across neurodegeneration and inflammation; provided knowledge transfer in lipidomics and mass spectrometry.

Project Scientist & Director, Analytical Discovery Facility2005 – 08/2011

Department of Pharmacology, University of California · Irvine, CA

Established and directed the Agilent Technologies/UC Irvine Analytical Discovery Facility — a cutting-edge LC/MS core unit supporting lipidomics and metabolomics research across neuroscience, endocannabinoid biology, and metabolic disease.
Co-authored 40+ peer-reviewed publications and co-invented 2 patents spanning lipidomics, endocannabinoid biology, and translational neuroscience.
Mentored and managed 10+ scientists, technicians, postdoctoral fellows, and Ph.D. students across a multidisciplinary research program.
Concurrent R&D partnerships:
- Agilent Technologies — co-developed novel lipidomics solutions using state-of-the-art LC/MS instrumentation
- Kadmus Pharmaceuticals (early-stage biotech) — drug discovery targeting inflammation, hepatic steatosis, and obesity
- ACD/Labs — developed software tools for lipidomic data processing and annotation

Research Scientist09/2003 – 2005

Department of Pharmacology, University of California · Irvine, CA

Initiated lipidomics and metabolomics capabilities in the Piomelli laboratory; developed and applied LC/MS-based methods to study endocannabinoid signaling, lipid mediators, and neurological disease models.
Promoted to Project Scientist and appointed Director of the Analytical Discovery Facility in recognition of scientific contributions and platform-building leadership.

Visiting Researcher01/2003 – 08/2003

Ben May Institute for Cancer Research, University of Chicago · IL

Conducted research in the laboratory of Prof. Guido Franzoso; explored transcriptional factors governing apoptosis using molecular biology and tissue culture techniques. J-1 visa sponsored by the University of Chicago — first position in the United States.

Chemist Specialist2002 – 2003

Italian Regional Agency for Environmental Protection · Caserta, Italy

Investigated freshwater contaminants using LC/MS, GC/MS, and HPIC.

Junior Specialist1999 – 2001

Zoological Station "Anton Dohrn" · Naples, Italy

Synthesized and evaluated nitro-catecholamine derivatives as potential inhibitors of neuronal nitric oxide synthase.
Concurrent research partnership with Dermatological Hospital San Gallicano (Rome): contributed to discovery of novel inhibitors of Nitric Oxide Synthase.

Early Career — Quality Control & Assurance2000 – 2002

Italy

QC/QA roles in pharmaceutical manufacturing and food packaging: DSM Bulk Pharmaceutics (Capua) — developed SOPs and conducted quality audits in a GMP environment; Icimen Due Food Packaging (Marcianise) — quality control analysis using Gas Chromatography.

Education

Ph.D. — Biochemistry and Molecular Biology

University of Rome "Tor Vergata" · Rome, Italy

"Multi-Organ Systems Lipidomics: a Liver Peroxisomal Dysfunction in Alzheimer's disease"

M.Sc. II — Analytical Chemistry: Quality Control & Assurance

University of Rome "La Sapienza" · Rome, Italy

"Analytical methods for freshwater environmental assessment in compliance with EU regulations"

M.Sc. I — Biochemistry

University of Naples "Federico II" · Naples, Italy

Final grade 110/110 — "Novel endogenous inhibitors of Neuronal Nitric Oxide Synthase"

B.Sc. — Chemistry

University of Naples "Federico II" · Naples, Italy

Academic Teaching Experience

2011–present — BCHB-596 Clinical Metabolomics; Lipidomics in translational research — Georgetown University

2007–2011 — Mass spectrometry techniques in pharmacology: Pharm254 — Graduate Program, University of California Irvine (Overall Evaluation Score: Excellent)

2001–2002 — Biochemistry and Organic Chemistry — Universitalia tutoring school, Rome, Italy

Grants & Awards

★Principal Investigator (proposal) — “Lipid and protein signatures to guide development of effective lysosome modulating therapies for Parkinson's disease,” Michael J. Fox Foundation Lysosomal Biomarkers Program, $350,000 over 2 years, submitted May 2023 (Arkuda Therapeutics)

★Tenured Associate Professor position offered — Chair of Research in Lipidomics, Department of Biological Sciences, Faculty of Science, University of Calgary, Canada, 2022 (declined to pursue industry role)

★National Scientific Qualification for University Teaching (Abilitazione Scientifica Nazionale — ASN), Associate Professor and Full Professor level, Analytical Chemistry and Biochemistry, Italy, 2020 — merit-based national qualification awarded by a panel of full professors, conferring eligibility for faculty positions at Italian universities

★State Certification in Chemistry (Esame di Stato — Abilitazione alla professione di Chimico), Italy, 2001 — nationally administered professional licensure examination

★"Lipidomic biosignature in Alzheimer's disease" — New Investigator Research Grant (NIRG-11-203674) from the Alzheimer's Association, 2011

★U.S. Permanent Resident — EB-1A (Extraordinary Ability in Science), U.S. Government, 2011

★Top New Investigator Award in Biochemistry of Lipids — International Society for the Study of Fatty Acids and Lipids (ISSFAL), Maastricht, 2010

★Career Award — University of California, Irvine, 2008

★Italian Region Campania Specialization Degree Studentship, 2002–2003

★Italian Ministry of Public Health Postgraduate Fellowship, 2001–2002

★Selected for Scuola Ufficiali dell'Esercito Italiano, Corpo degli Ingegneri — commissioned as Officer Lieutenant (Sottotenente), Italian Army Corps of Engineers, 2001–2002

Professional Societies

International Society for the Study of Fatty Acids and Lipids (ISSFAL)

American Chemical Society

American Oil Chemists' Society (AOCS)

Euro Fed Lipids

Society for Neuroscience

American Society for Mass Spectrometry (ASMS)

Metabolomics Society

Editorial & Reviewing Activity

External Referee

Cell Reports · Neuron · Cell · Nature Protocols · Analytical Chemistry · Analytical and Bioanalytical Chemistry · Bioanalysis · PLOS ONE · Journal of Mass Spectrometry · Journal of Lipid Research · Metabolomics · Journal of Chromatography B · Prostaglandins-Leukotrienes-and-Essential-Fatty-Acids · Biofactors · European Journal of Pharmacology · Neuropharmacology · Journal of Pharmacology and Experimental Therapeutics · Molecular Psychiatry · Journal of Nutrition and Metabolism · Dementia and Geriatric Cognitive Disorders · Current Gerontology and Geriatrics Research · Sultan Qaboos University Medical Journal · Frontiers in Cardiovascular Medicine

Grant Reviewing

National Institutes of Health (NIH) · Alzheimer's Association · Human Frontier Science Program (HFSP) · Cognitive Sciences Call of the Vienna Science and Technology Fund · Research Foundation Flanders · ZonMw — Netherlands Organisation for Health Research and Development

Editorial Roles

Editor — Ion Mobility-Mass Spectrometry, Springer, September 2019

Editor — Special Issue "Lipids in Neurodegenerative Disorders", International Journal of Molecular Sciences, October 2022

Editor — Special Issue "Bioactive Lipids and Lipidomics", International Journal of Molecular Sciences, 2015

Member of Editorial Board — Frontiers in Membrane Physiology and Biophysics

Patents & Disclosures

Astarita G, Di Paolo G, Lin KL, Monroe KM, Nugent AA, Van Lengerich B, et al. Methods for treating dysregulated lipid metabolism. WO2020112889 (2021)

Astarita G, Devos SL, Di Paolo G, Logan TP, Wang J, et al. Methods for treating and monitoring progranulin-associated disorders. US 17/284,764; WO2020081575 (2021)

Astarita G, Dennis MS, Getz JA, Henry A, Kariolis M, et al. Fusion proteins comprising enzyme replacement therapy enzymes. US 17/102,138; WO/2019/070577A1 (2021)

Arguello A, Astarita G, Bhalla A, Blumenfeld JR, Di Paolo G, et al. Lysosomal Storage Disorder Biomarkers and Methods of Use Thereof. WO2020123511 (2020)

Astarita G. Profile diagnostics in personalized dermatology, dermatopathology and cosmetics. US Patent 20170003268 (2019)

Astarita G. Monitoring radiation exposure and radiosensitivity using ambient ionization mass spectrometry. WO2018009700A1 (2018)

Astarita G, Geromanos S. Chemical class compositions from collision cross-section fragment ions. WO2018005948A1 (2018)

Astarita G. Molecular diagnostics in personalized dermatology, dermatopathology and cosmetics. US Patent 20170004957; US9881777B2 (2018)

Astarita G, Mason D, Balogh M. Free and total fatty acid determination using desorption ionization-mass spectrometry. US20160349233 (2018)

Olivos H, Astarita G. Method to improve the identification, quantification and spatial localization of multiply charged molecules using ion mobility. US20170254777A1 (2017)

Astarita G, Brousmiche DW. Method of using chemical tags to improve the identification, quantification and spatial localization of components in a sample. WO2017143158A1 (2017)

Astarita G, Mason D, Balogh M. Essential nutrient ratio determination. WO/2016/196179A1 (2016)

Astarita G. Metabolic pathway and metabolite identification. WO/2016/196183A1 (2016)

Astarita G, Geromanos S. Mass spectrometry with quadrupole and ion mobility separation capabilities. WO/2016/196181A1 (2016)

Astarita G. Structural elucidation of isotopically labeled analytes. WO/2016/168391A1 (2016)

Piomelli D, Astarita G, Avanesian A, Cavalli A. Methods of treatment for methamphetamine toxicity targeting ceramide metabolic pathways and cellular senescence. WO 2013149250 A1 (2013)

Delivering docosahexaenoic acid to the brain as therapy for cognitive dysfunctions. Disclosure UC Case No. 2010-526-1. UC Irvine, 2010.

Lipidomic biomarkers for Alzheimer's disease. Disclosure UC Case No. 2009-482-1. UC Irvine, 2009.

Peer-Reviewed Publications

Complete list: PubMed · Google Scholar · ORCID

Root J, Mendsaikhan A, Taylor G, Merino P, Nandy S, Wang M, Araujo LT, Ryu D, Holler C, Thompson BM, Astarita G, Blain JF, Kukar T. Granulins rescue inflammation, lysosome dysfunction, lipofuscin, and neuropathology in a mouse model of progranulin deficiency. Cell Reports. 2024 Dec 24;43(12):114985.

Astarita G, Kelly RS, Lasky-Su J. Metabolomics and lipidomics strategies in modern drug discovery and development. Drug Discovery Today. 2023 Oct;28(10):103751.

Thompson BM, Astarita G. High-Throughput Lipidomic and Metabolomic Profiling for Brain Tissue and Biofluid Samples in Neurodegenerative Disorders. Methods Mol Biol. 2024;2785:221-260.

Bossi E, Limo E, Pagani L, Monza N, Serrao S, Denti V, Astarita G, Paglia G. Revolutionizing Blood Collection: Innovations, Applications, and the Potential of Microsampling Technologies for Monitoring Metabolites and Lipids. Metabolites. 2024;14(1):46.

Xia D, Lianoglou S, Sandmann T, Calvert M, Suh JH, ... Astarita G, et al. Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. Mol Neurodegener. 2022;17(1):41.

Jennings D, Huntwork-Rodriguez S, Henry AG, ... Astarita G, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. Sci Transl Med. 2022;14(648):eabj2658.

Logan T, Simon MJ, Rana A, ... Astarita G, et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184(18):4651-4668.

Paglia G, Smith AJ, Astarita G. Ion mobility mass spectrometry in the omics era: Challenges and opportunities for metabolomics and lipidomics. Mass Spectrom Rev. 2021.

Savas B, Astarita G, Aureli M, Sahali D, Ollero M. Gangliosides in Podocyte Biology and Disease. Int J Mol Sci. 2020;21(24):E9645.

Crotty GF, Maciuca R, Macklin EA, Wang J, ... Astarita G, Schwarzschild MA. Association of caffeine and related analytes with resistance to Parkinson's disease among LRRK2 mutation carriers. Neurology. 2020;95(24):e3428-e3437.

Wang J, Bhalla A, Ullman JC, Fang M, ... Astarita G. High-Throughput LC-MS/MS Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II. Int J Mol Sci. 2020;21(15):5449.

Bhalla A, Ravi R, Fang M, ... Astarita G, et al. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients. Int J Mol Sci. 2020;21(15):E5188.

Andreone BJ, Przybyla L, Llapashtica C, ... Astarita G, Di Paolo G, et al. Alzheimer's-associated PLCγ2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nature Neuroscience. 2020;23(8):927-38.

Ullman JC, ... Astarita G, et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Science Translational Medicine. 2020;12(545):eaay1163.

Nugent AA, ... Astarita G, Lewcock JW, Monroe KM, Di Paolo G. TREM2 Regulates Microglial Cholesterol Metabolism Upon Chronic Phagocytic Challenge. Neuron. 2020;105(5):837-54.

Oniszczuk J, Sendeyo K, Chhuon C, ... Astarita G, Sahali D, Ollero M. CMIP is a negative regulator of T cell signaling. Cell Mol Immunol. 2019.

Fasciotti M, Souza GHMF, Astarita G, et al. Investigating the Potential of Ion Mobility-Mass Spectrometry for Microalgae Biomass Characterization. Anal Chem. 2019;91(14):9266-9276.

Paglia G, Astarita G. Traveling Wave Ion Mobility Mass Spectrometry: Metabolomics Applications. Methods Mol Biol. 2019;1978:39-53.

Laiakis EC, Canadell MP, Grilj V, ... Astarita G, Fornace AJ Jr. Serum lipidomic analysis from mixed neutron/X-ray radiation fields reveals a hyperlipidemic and pro-inflammatory phenotype. Sci Rep. 2019;9(1):4539.

Astarita G, Stocchero M, Paglia G. Unbiased Lipidomics and Metabolomics of Human Brain Samples. Methods Mol Biol. 2018;1750:255-269.

Laiakis EC, Pannkuk EL, Chauthe SK, Wang YW, ... Astarita G, Fornace AJ Jr. A Serum Small Molecule Biosignature of Radiation Exposure from Total Body Irradiated Patients. J Proteome Res. 2017.

Paglia G, Astarita G. Metabolomics and lipidomics using traveling-wave ion mobility mass spectrometry. Nature Protocols. 2017;12(4):797-813.

Einarsdottir E, Magnusdottir M, Astarita G, et al. Metabolic Profiling as a Screening Tool for Cytotoxic Compounds from Sponges. Mar Drugs. 2017;15(2):52.

Bellet MM, Masri S, Astarita G, Sassone-Corsi P, Servillo G. SIRT1 Controls Proliferation, Circadian Rhythm and Lipid Metabolism during Liver Regeneration. J Biol Chem. 2016.

Pannkuk EL, Laiakis EC, Mak TD, Astarita G, et al. A lipidomic and metabolomic serum signature from nonhuman primates exposed to ionizing radiation. Metabolomics. 2016;12(5).

Paglia G, Stocchero M, Cacciatore S, ... Astarita G. An unbiased metabolomic investigation of the Alzheimer's disease brain points to a dysregulation of the mitochondrial aspartate metabolism. J Proteome Res. 2016.

Yu T, Taussig MD, DiPatrizio NV, Astarita G, et al. Deficiency of Lipoprotein Lipase in Neurons Decreases AMPA Receptor Phosphorylation. PLoS One. 2015;10(8):e0135113.

Maldini M, Natella F, Baima S, ... Astarita G. Untargeted Metabolomics Reveals Predominant Alterations in Lipid Metabolism Following Light Exposure in Broccoli Sprouts. Int J Mol Sci. 2015;16:13678-13691.

Astarita G, Ollero M. Lipidomics: An Evolving Discipline in Molecular Sciences. Int J Mol Sci. 2015;16(4):7748-7752.

Paglia G, Kliman M, Claude E, Geromanos S, Astarita G. Applications of Ion-Mobility Mass Spectrometry in Lipid Analysis. Anal Bioanal Chem. 2015;407(17):4995-5007.

Watschinger K, Keller MA, ... Astarita G, Ralser M, Werner ER. Tetrahydrobiopterin and alkylglycerol monooxygenase substantially alter the murine macrophage lipidome. PNAS. 2015;112(8):2431-6.

Astarita G, Avanesian A, Grimaldi B, Realini N, ... Piomelli D. Methamphetamine Accelerates Cellular Senescence through Stimulation of De Novo Ceramide Biosynthesis. PLoS One. 2015;10(2):e0116961.

Pacini T, Fu W, Gudmundsson S, ... Astarita G, Paglia G. A multidimensional analytical approach based on UHPLC-UV-ion mobility-MS for the screening of natural pigments. Anal Chem. 2015;87(5):2593-9.

Paglia G, Angel P, Williams JP, Richardson K, Olivos HJ, ... Astarita G. Ion Mobility-Derived Collision Cross Section As an Additional Measure for Lipid Fingerprinting and Identification. Anal Chem. 2015;87(2):1137-44.

Astarita G, Kendall AC, Dennis EA, Nicolaou A. Targeted lipidomics strategies for oxygenated metabolites of polyunsaturated fatty acids. Biochim Biophys Acta. 2015;1851(4):456-468.

Laiakis EC, Strassburg K, Bogumil R, ... Astarita G. Metabolic Phenotyping Reveals a Lipid Mediator Response to Ionizing Radiation. J Proteome Res. 2014;13(9):4143-54.

Astarita G, McKenzie JH, Wang B, Strassburg K, ... Langridge J, Kang JX. A Protective Lipidomic Biosignature Associated with a Balanced Omega-6/Omega-3 Ratio in fat-1 Transgenic Mice. PLoS One. 2014;9(4):e96221.

Paglia G, Williams JP, Menikarachchi L, ... Astarita G. Ion Mobility Derived Collision Cross Sections to Support Metabolomics Applications. Anal Chem. 2014;86(8):3985-93.

Sahar S, Masubuchi S, Eckel-Mahan K, ... Astarita G, Piomelli D, Sassone-Corsi P. Circadian Control of Fatty Acid Elongation by SIRT1. J Biol Chem. 2014;289(9):6091-7.

Astarita G, Langridge J. An Emerging Role for Metabolomics in Nutrition Science. J Nutrigenet Nutrigenomics. 2013;6:179-198.

Bellet MM, Nakahata Y, Boudjelal M, ... Astarita G, Sassone-Corsi P. Pharmacological modulation of circadian rhythms by synthetic activators of SIRT1. PNAS. 2013.

Paglia G, Menikarachchi LC, Langridge J, Astarita G. Travelling-wave ion mobility-mass spectrometry in metabolomics: workflows and bioinformatic tools. In: Identification and Data Processing Methods in Metabolomics (Rudaz S, Ed.). Future Medicine, London, UK. 2013.

Astarita G, Paglia G. Applications of ion mobility mass spectrometry in metabolomics. In: Advanced LC-MS Applications in Metabolomics (Borchers C, Han J, Parker C, Eds.). Future Medicine, London, UK. 2013.

Jung KM, Clapper JR, Fu J, ... Astarita G, Piomelli D. 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab. 2012;15(3):299-310.

Snigdha S, Astarita G, Piomelli D, Cotman CW. Effects of dietary and behavioral enrichment on free fatty acids in aged canine brain. Neuroscience. 2012;202:326-33.

Cippitelli A, Astarita G, Duranti A, ... Piomelli D, Ciccocioppo R. Endocannabinoid regulation of acute and protracted nicotine withdrawal. PLoS One. 2011;6(11):e28142.

Snigdha S, Berchtold N, Astarita G, et al. Dietary and Behavioral Interventions Protect against Age Related Caspase Cascades in the Canine Brain. PLoS One. 2011;6(9):e24652.

Astarita G, Jung KM, DiPatrizio NV, ... Head E, Cotman CW, Piomelli D. Elevated Stearoyl-CoA Desaturase in Alzheimer's Disease. PLoS One. 2011;6(10):e24777.

Astarita G, Piomelli D. Lipidomics of Alzheimer's disease: a liver peroxisomal dysfunction in the metabolism of omega-3 fatty acids. Oléagineux Corps gras Lipides (OCL). 2011;18(4).

DiPatrizio NV, Astarita G, Li X, Schwartz GJ, Piomelli D. A peripheral endocannabinoid mechanism enhances dietary fat intake. PNAS. 2011;108(31):12904-8.

Astarita G, Piomelli D. Towards a whole-body systems lipidomics in Alzheimer's disease. Prostaglandins Leukot Essent Fatty Acids. 2011;85(5):197-203.

Ollero M, Guerrera IC, Astarita G, Piomelli D, Edelman A. New lipidomic approaches in cystic fibrosis. Methods Mol Biol. 2011;742:265-78.

Jung KM, Astarita G, Thongkham D, Piomelli D. Diacylglycerol lipase-α and -β control neurite outgrowth in Neuro-2a cells. Mol Pharmacol. 2011;80(1):60-7.

Di Sabatino A, Battista N, Biancheri P, ... Astarita G, Piomelli D, Maccarrone M, Corazza G. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol. 2011.

Jung KM*, Astarita G*, Yasar S, ... Head E, Cotman CW, Piomelli D. An Amyloid β42-dependent deficit in anandamide production is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol Aging. 2011. *equal contribution

Ollero M, Astarita G, Sermet-Gaudelus I, ... Piomelli D, Edelman A. Plasma lipidomics reveals potential prognostic signatures in cystic fibrosis. J Lipid Res. 2011;52(5):1011-22.

Fu J, DiPatrizio N, Guijarro A, ... Astarita G, Piomelli D. Sympathetic activity controls fat-induced OEA signaling in small intestine. J Neurosci. 2011;31(15):5730-6.

Wang H, Astarita G, Taussig MD, ... Goldberg IJ, Eckel RH. Deficiency of lipoprotein lipase in neurons modifies energy balance regulation. Cell Metab. 2011;13(1):105-13.

Grimaldi B, Bellet M, Katada S, Astarita G, ... Sassone-Corsi P. PER2 controls lipid metabolism by direct regulation of PPARγ. Cell Metab. 2010;12(5):509-20.

Murphy MP, Morales J, Beckett CL, Astarita G, Piomelli D, ... Head E. Changes in Cognition and amyloid-beta Processing with Long Term Cholesterol Reduction in Aged Dogs. J Alzheimers Dis. 2010;22(1):135-50.

Astarita G, Jung CM, Berchtold NC, Nguyen VQ, ... Head E, Cotman CW, Piomelli D. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One. 2010;5(9):e12538.

Solorzano C, Zhu C, Battista N, Astarita G, ... Piomelli D. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. PNAS. 2009;106(49):20966-71.

Guerrera IC, Astarita G, Jais JP, Sands D, ... Piomelli D, Edelman A, Ollero M. A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients. PLoS One. 2009;4(11):e7735.

Guijarro A, Fu J, Astarita G, Piomelli D. CD36 gene deletion decreases oleoylethanolamide levels in small intestine of free-feeding mice. Pharmacol Res. 2010;61(1):27-33.

Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian Control of the NAD+ Salvage Pathway. Science. 2009;324(5927):654-7.

Astarita G, Geaga J, Ahmed F, Piomelli D. Targeted lipidomics as a tool to investigate endocannabinoid function. Int Rev Neurobiol. 2009;85:35-55.

Astarita G, Piomelli D. Lipidomic analysis of endocannabinoid metabolism in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(26):2755-67.

Astarita G, Ahmed F, Piomelli D. Lipidomic analysis of biological samples by liquid chromatography coupled to mass spectrometry. Methods Mol Biol. 2009;579:201-19.

Campolongo P, Roozendaal B, Trezza V, Cuomo V, Astarita G, Fu J, McGaugh JL, Piomelli D. The fat-induced satiety factor OEA enhances memory consolidation. PNAS. 2009;106(19):8027-31.

Schwartz JG, Fu J*, Astarita G*, Li X, ... Piomelli D. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab. 2008;8(4):281-8. *equal contribution

Moise A, Eisenstein S, Astarita G, Piomelli D, Hohmann A. An Endocannabinoid Signaling System Modulates Anxiety-like Behavior in Male Syrian Hamsters. Psychopharmacology. 2008;200(3):333-46.

Fu J, Kim J, Oveisi F, Astarita G, Piomelli D. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol. 2008;295(1):R45-50.

Potvin S, Kouassi E, Lipp O, ... Astarita G, Piomelli D, Stip E. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol. 2008;22(3):262-9.

Astarita G, Ahmed F, Piomelli D. Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. J Lipid Res. 2008;49(1):48-57.

Piomelli D, Astarita G, Rapaka R. A neuroscientist's guide to lipidomics. Nature Reviews Neuroscience. 2007;8(10):743-54.

Tarzia G, Antonietti F, Duranti A, Tontini A, Mor M, Rivara S, Traldi P, Astarita G, King A, Clipper JR, Piomelli D. Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). Ann Chim. 2007;97(9):887-94.

Jung KM*, Astarita G*, Zhu C, Mackie K, Piomelli D. A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol. 2007;72(3):612-21. *equal contribution

Makara JK, Mor M, Fegley D, ... Astarita G, Freund TF, Piomelli D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci. 2007;10(1):134.

Schreiber D, Harlfinger S, Nolden BM, Gerth CW, Jaehde U, Schomig E, Klosterkotter J, Giuffrida A, Astarita G, Piomelli D, Leweke FM. Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem. 2007;361(2):162-8.

Fu J*, Astarita G*, Gaetani S, Kim J, Cravatt BF, Mackie K, Piomelli D. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem. 2007;282(2):1518-28. *equal contribution

Astarita G, Di Giacomo B, Gaetani S, Oveisi F, Compton TR, Rivara S, Tarzia G, Mor M, Piomelli D. Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther. 2006;318(2):563-70.

Astarita G, Rourke BC, Andersen JB, Fu J, Kim JH, Bennett AF, Hicks JW, Piomelli D. Postprandial increase of oleoylethanolamide mobilization in small intestine of the Burmese python. Am J Physiol Regul Integr Comp Physiol. 2006;290(5):R1407-12.

Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor PPAR-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-9.

Palumbo A, Astarita G, d'Ischia M. Inhibition of neuronal nitric oxide synthase by 6-nitrocatecholamines. Biochem J. 2001;356(Pt 1):105-10.

Palumbo A, Astarita G, Picardo M, d'Ischia M. Ni2+, a Double-Acting Inhibitor of Neuronal Nitric Oxide Synthase. Biochem Biophys Res Commun. 2001;285(1):142-6.

Book Chapters

Ghaste M, Mattivi F, Astarita G, Shulaev V. Analysis of Grape Volatiles Using Atmospheric Pressure Ionization GC-MS-Based Metabolomics. Methods in Molecular Biology. 2022.

Paglia G, Astarita G. A High-Throughput HILIC-MS-Based Metabolomic Assay for the Analysis of Polar Metabolites. Methods in Molecular Biology. 2022.

Astarita G, Dhungana S, Shrestha B, Laiakis EC. Metabolomic approaches to study the tumor microenvironment. Methods in Enzymology. 2020.

Paglia G, Astarita G. Ion Mobility-Mass Spectrometry for Lipid Analysis. New Developments in Mass Spectrometry. RSC Publishing, 2020.

Paglia G, Astarita G. Traveling Wave Ion Mobility Mass Spectrometry: Metabolomics Applications. Methods in Molecular Biology: High-Throughput Metabolomics. 2019.

Astarita G, Stocchero M, Paglia G. Unbiased Lipidomics and Metabolomics of Human Brain Samples. Methods in Molecular Biology: Biomarkers for Alzheimer's Disease Drug Development. 2018.

Paglia G, Shrestha B, Astarita G. Ion-mobility mass spectrometry for lipidomics applications. Neuromethods — Lipidomics. 2017.

Paglia G, Menikarachchi LC, Langridge J, Astarita G. Traveling-wave ion mobility-mass spectrometry in metabolomics. Future Science Book Series. 2015.

Ollero M, Guerrera IC, Astarita G, Piomelli D, Edelman A. New lipidomic approaches in cystic fibrosis. Methods in Molecular Biology, vol. 742. 2011.

Astarita G, Ahmed F, Piomelli D. Lipidomic analysis of biological samples by liquid chromatography coupled to mass spectrometry. Methods in Molecular Biology, vol. 579. 2009.

Astarita G, Geega J, Ahmed F, Piomelli D. Targeted Lipidomics as a Tool to Investigate Endocannabinoid Function. International Review of Neurobiology, vol. 85. Elsevier, 2009.

Application Notes

Organtini K, Astarita G, Cleland G. Rapid Screening of Fatty Acids in Oil Supplements Using Ambient Ionization (DART) and Mass Detection. Waters Corporation, 2016.

Metabolomics & Lipidomics Application Notebook. Waters Corporation, 2015.

Shulaev V, Ghaste M, Lai S, … Langridge J, Plumb R, Mattivi F, Astarita G. Metabolic Phenotyping Using Atmospheric Pressure Gas Chromatography-MS. Waters Corporation, 2015.

Arapitsas P, Langridge J, Mattivi F, Astarita G. A Facile Database Search Engine for Metabolite Identification in Metabolomics. Waters Corporation, 2014.

Broccardo C, Murphy JP, Astarita G, Prenni J. Multiplexed Analysis of Steroid Hormones Using ionKey/MS. Waters Corporation, 2014.

Astarita G, Doneanu A, Johnson J, Murphy J, Langridge J. Targeted Lipidomics Using the ionKey/MS System. Waters Corporation, 2014.

Jones MD, Isaac G, Astarita G, Aubin A, Shockcor J, Shulaev V, Legido-Quigley C, Smith N. Lipid Class Separation Using UPC²/MS. Waters Corporation, 2013.

Astarita G, Netto J, Isaac G, Gorenstein MV, Ritchie M, Langridge J. A Multidimensional Lipidomics Method: HILIC Coupled with Ion Mobility Enabled Time-of-Flight MS. Waters Corporation, 2013.

Maldini M, Baima S, Natella F, Scaccini C, Langridge J, Astarita G. Metabolomics of broccoli sprouts using UPLC with ion mobility LC-MS^E. Waters Corporation, 2013.

Strassburg K, Molloy BJ, Mallet C, … Astarita G. Targeted lipidomics of oxygenated fatty acids (oxylipins). Waters Corporation, 2013.

Krechmer J, Neeson KJ, Isaac G, Tice J, … Astarita G. Real-Time Lipidomic Profiling Using Desorption Ionization with Ion Mobility MS. Waters Corporation, 2013.

Paglia G, Langridge J, Astarita G. Development of a Metabolomic Assay for the Analysis of Polar Metabolites Using HILIC UPLC/QTof MS. Waters Corporation, 2013.

Laiakis EC, Bogumil R, … Astarita G. Targeted Metabolomics using the UPLC-MS-based AbsoluteIDQ® p180 Kit. Waters Corporation, 2012.

Isaac G, McDonald S, Astarita G. Localization of double bond position in acyl chains of complex lipids by UPLC/HDMS^E. Waters Corporation, 2011.

Isaac G, McDonald S, Astarita G. Automated lipid identification using UPLC/HDMS^E in combination with SimLipid. Waters Corporation, 2011.

Isaac G, McDonald S, Astarita G. Lipid Separation using UPLC with Charged Surface Hybrid Technology. Waters Corporation, 2011.

Astarita G, Xiao H, Geaga J, Ahmed F, Piomelli D. Implementing micro- and nano-LC/MS techniques for high-sensitivity lipidomic analysis. Agilent Measurement Journal. May 2008, Issue 5.

Other Publications & Media

Astarita G. Metabolomics in drug and biomarker discovery. Drug Target Review. September 2018.

Shrestha B., Astarita G. Desorption and Ionization Mass Spectrometry in Research Laboratories. LCGC. April 2016.

Shrestha B., Astarita G. The rising of ambient-ionization mass spectrometry for metabolomics and lipidomics. MetaboNews. April 2016.

Astarita G. Metabolomics In Food And Nutrition Laboratories. Spectroscopy. February 2016.

Interviewed by Biocompare on Waters Lipidomics solutions. 2016.

Paglia G, Astarita G. Ion-Mobility Mass Spectrometry in Metabolomics and Lipidomics. LCGC. September 2015.

Interview with Giuseppe Astarita. International Innovation. January 2015.

Astarita G. Metabolomics In Food And Nutrition Laboratories. LCGC. April 2014.

Interview with Giuseppe Astarita. MetaboNews. January 2014.

Astarita G. The omega-3 Odyssey. The Analytical Scientist. September 2013, Issue #0813.

Astarita G, Yu K. New Frontiers for Mass Spectrometry in Lipidomics, Part II. LCGC. Jun 2012.

Astarita G, Yu K. New Frontiers for Mass Spectrometry in Lipidomics, Part I. LCGC. Feb 2012.

Webinars & Podcasts

Astarita G. Metabolomics in biomarker discovery and functional genomics. Biocrates Webinar. January 26, 2023.

Astarita G. New metabolomics and microbiome research innovations that will change how we view the gut microbiota. Metabolon Webinar. November 15, 2021.

Astarita G. Advancing your drug development with metabolomics. C&EN / ACS Webinar. August 11, 2021.

Astarita G. Unique advantages of incorporating untargeted and targeted metabolomics in drug development and clinical trials. European Pharmaceutical Review Webinar. January 20, 2021.

Astarita G. Spatial Metabolomics of Alzheimer Diseased Brains by LAESI-MS. Protea Biosciences Webinar. October 23, 2014.

Astarita G. Ion Mobility Derived Collision Cross Sections to Support Metabolomics and Lipidomics. Waters Corporation Webinar. October 2014.

Astarita G. Metabolomics and Lipidomics Strategies for Clinical Research and Biomarker Discovery. Bioanalysis Zone MTB Spotlight Webinar. December 2014.

Astarita G, Xiao H, Geaga J, Ahmed F, Piomelli D. Implementing micro- and nano-LC/MS techniques for high-sensitivity lipidomic analysis. Agilent Measurement Journal, May 2008.

Invited Talks

"Technological Innovations in Metabolomics analysis"

American Association of Pharmaceutical Sciences (AAPS) · Denver, CO · November 2016

"Emerging Metabolomics and Lipidomics Approaches: Applications in Biomedical and Clinical Research"

IBC and National Center of Research (CNR) · Pozzuoli, Naples, Italy · April 2016

"Emerging Metabolomics and Lipidomics Approaches: what's next"

Washington-Baltimore Mass Spectrometry Discussion Group · February 2016

"Emerging Lipidomics and metabolomics approaches in Cancer research"

Dana-Farber Cancer Institute · Boston, MA · July 2015

"Metabolomics and Lipidomics approaches for biomedical research and biomarker discovery"

ASMS Waters Users Meeting · Saint Louis, MO · May 2015

"A unique brain lipidome and metabolome biosignature in Alzheimer's Disease?"

Brain and Lipids III, Journées CHEVREUL · Paris, France · March 2015

"A Role for Lipids and Lipidomics in Health and Disease"

Imperial College · London, UK · January 2015

"Ion Mobility to support Metabolomics and Lipidomics"

iConference MS · China · November 2014

"Novel orthogonal technologies in support of mass spectrometry-based lipid analysis"

American Oil Chemical Society (AOCS) · San Antonio, TX · May 2014

"Markers of health and wellness"

Allergan · Irvine, CA · March 2014

"Markers of health and wellness: A protective molecular biosignature linked to a balanced omega-6/omega-3 ratio"

Georgetown University Medical Center · February 2014

"Lipidomics of 'Omega-3 mice' reveals a panel of anti-inflammatory and pro-resolving mediators"

Bascom Palmer Eye Institute, University of Miami · January 2014

"Ion Mobility in Metabolomics and Lipidomics"

Lake Louise Tandem Mass Spectrometry Workshop · Alberta, Canada · December 2013

"Lipidomics of 'Omega-3 mice' reveals a panel of anti-inflammatory and pro-resolving mediators"

University of Alberta · Edmonton, Canada · December 2013

"Innovative Omics Solutions"

Washington-Baltimore MS Discussion Group · September 2013

"New Frontiers for Metabolomics in Research Labs"

Second University of Naples · Caserta, May 2013

"Metabolomics Approaches using Ion Mobility MS"

First Belgian-Netherlands Symposium on Metabolomics · Spa, May 2013

"Advanced Analytical Solutions in Metabolomics and Lipidomics"

DSM Nutritional Products · April 2013

"New frontiers for MS in Metabolomics"

Netherlands Metabolomics Center · Breukelen, The Netherlands · December 2012

"New frontiers for lipidomics in translational medicine"

University of Iceland · September 2012

"Ion Mobility Lipidomics"

Conference on Small Molecules Science (CoSMoS) · Providence, RI · September 2012

"New Frontiers for Metabolomics in Translational Medicine"

Bascom Palmer Eye Institute, University of Miami · August 2012

"New Frontiers for Metabolomics in Translational Medicine"

Saint-Petersburg, Russian Federation · June 2012

"New Frontiers for Lipidomics in Translational Research"

Columbia University Center for Radiation Biodosimetry · New York · April 2012

"New Frontiers for Lipidomics in Translational Research"

Georgetown University Medical Center · October 2011

"Lipidomics of Alzheimer's disease: a liver peroxisomal dysfunction in the metabolism of omega-3 fatty acids"

Journées Chevreul 2011, Lipids & Brain 2 · Paris, France · March 2011

"Lipidomic biosignatures in Alzheimer's disease"

INSERM, Faculté de Médecine Paris Descartes · Paris, France · March 2011

"Deficient liver biosynthesis of docosahexaenoic acid in Alzheimer's disease"

ISSFAL · Maastricht, The Netherlands · June 2010

"A liver dysfunction in Alzheimer's disease"

Italian Institute of Technology · Genoa, Italy · December 2009

"The lipidomics of Alzheimer's disease: omega-3 fatty acids link cognition with liver metabolism"

Johannes Gutenberg-University Mainz · Germany · July 2009

"Omega-3 fat deficit in Alzheimer's disease links brain and liver metabolism"

UC Irvine Alzheimer's Disease Research Center · May 2009

"A metabolic disorder beyond Alzheimer's disease"

Italian Institute of Technology · Genoa, Italy · 2008

"A new metabolic component of Alzheimer's Disease"

UC Irvine Institute of Brain Aging and Dementia · 2008

"Lipid alterations in Alzheimer's disease"

UC Irvine Alzheimer's Disease Research Center · 2007

"LC-MS of lipids in biological samples"

LC-MS Discussion Group · Toronto, Canada · November 2007

Short Courses

American Oil Chemical Society (AOCS) · Orlando, Florida · May 2017

6th European Workshop on Lipid Mediators · Frankfurt, Germany · September 2016

NATO SPS ASI School on Molecular Technologies for Detection of Chemical and Biological Agents · Campora San Giovanni, Italy · April 2016

International Summer School on Natural Products · Naples, Italy · July 2015

Nordic Lipid Forum Academy · Reykjavik, Iceland · June 2015

American Oil Chemical Society (AOCS) · Orlando, Florida · May 2015

Imperial College · London, UK · January 2015

Fifth European Workshop on Lipid Mediators · Istanbul, Turkey · October 2014

ISSFAL · Stockholm, Sweden · July 2014

American Oil Chemical Society (AOCS) · San Antonio, TX · May 2014

Euro Fed Lipids · Antalya, Turkey · October 2013

54th Annual Meeting, American Society of Pharmacognosy · Saint Louis, MO · July 2013

Predictive, Personalized, Preventive Medicine Conference · St Petersburg, Russia · June 2012

Major Conference Oral Communications

"Markers of Health: Molecular Phenotyping Unveils the Healthy Biosignature of 'Omega-3' Transgenic Mice"

AOCS · Salt Lake City · May 2016

"Unbiased Lipidomics Reveals a Key Role for De Novo Ceramide Biosynthesis in Methamphetamine-Induced Systemic Inflammation"

Gordon Research Conference: Glycolipid and Sphingolipid Homeostasis · Lucca, Italy · March 2016

"An Unbiased Investigation of the Lipidomic and Metabolomic Pathways Altered in Alzheimer's Disease Brain"

MSACL · Palm Springs, CA · February 2016

"Metabolomic Phenotyping reveals a Lipid Mediator Response to Ionizing Radiation"

MSACL EU · Salzburg, Austria · September 2015

"Metabolic Phenotyping reveals a Lipid Mediator Response to Ionizing Radiation"

8th Nordic Lipidforum Symposium · Reykjavik, Iceland · June 2015

"Targeted Lipidomics using a Novel Integrated Microfluidics-Mass Spectrometry Technology"

ISSFAL · Stockholm, Sweden · June 2014

"A unique brain lipidome and metabolome biosignature in Alzheimer's Disease"

Metabolomics International Conference · Tsuruoka, Japan · June 2014

"Spatial Metabolomics of Alzheimer's Disease Brains using LAESI-MS"

ASMS · Baltimore, MD · June 2014

"A protective molecular biosignature linked to a balanced omega-6/omega-3 ratio"

MSACL · San Diego, CA · February 2014

"Lipidomics reveals a pattern of beneficial lipid alterations in the fat-1 transgenic mouse"

Euro Fed Lipid Meeting · Antalya, Turkey · October 2013

"A Prototype Microfluidic MS Platform for Metabolomics"

Metabolomics International Conference · Glasgow, UK · July 2013

"Lipidomics Profiling Unveils the Molecular Phenotype of 'Omega-3' Transgenic Mice"

27th Nordic Lipid Forum Congress · Helsinki, Finland · June 2013

"Lipidomics approaches: Omega-3 Transgenic Mice"

2nd International Congress of Translational Research in Human Nutrition · Clermont-Ferrand, France · March 2013

"Real time fatty acid profiling using ion mobility separation coupled to mass spectrometry"

ISSFAL · Vancouver, Canada · May 2012

Conference Posters

86 poster communications at major international conferences. Selected highlights below; complete list available on Google Scholar.

Crotty GF, Chang YT, Macklin EA, Maciuca R, Wang J, Montalban M, Davis SS, Alkabsh JI, Bakshi R, Chen X, Ascherio A, Astarita G, Huntwork-Rodriguez S, Schwarzschild MA. Metabolomic markers of the kynurenine and polyamine pathways are altered in Parkinson's disease independent of LRRK2 status. Neurology / AAN · May 2022.

Simon MJ, Logan T, ..., Astarita G, Sanchez PE, Meisner R, Diaz D, Henne K, Scearce-Levie K, Watts RJ, Henry AG, Kannan G, Suh JH, Lewcock JW, DeVos SL, Di Paolo G. Rescue of lysosomal storage disorder phenotypes caused by Grn loss of function with a brain penetrant progranulin biologic. Society for Neuroscience 2021 · 2021.

Ullman JC, Nugent AA, Arguello A, Bhalla A, ..., Astarita G, Di Paolo G, et al. Novel FACS based method demonstrates CNS cell-type distribution and efficacy of a BBB penetrant ERT in a mouse model of MPS II. Molecular Genetics and Metabolism · 2020.

Ghaste M, Mattivi F, Astarita G, Shulaev V. GC Atmospheric Pressure Ionization MS (APGC-MS) based metabolomics study of grape volatiles. 10th Symposium In Vino Analytica Scientia · 2017.

Laiakis EC, Pannkuk EL, Chauthe SK, Wang YW, ..., Astarita G, Fornace AJ Jr. Untargeted and targeted multiplatform metabolomic and lipidomic approaches for monitoring biological effects in serum from total body irradiated humans. AACR 2017 · Washington, D.C. · April 2017.

Pannkuk EL, Laiakis EC, Mak TD, Astarita G, Authier S, Wong K, Fornace AJ Jr. A Lipidomic and Metabolomic Serum Signature from Nonhuman Primates Exposed to Ionizing Radiation. Radiation Research 2016 · Hawaii · October 2016.

Laiakis EC, Strassburg K, ..., Fornace AJ Jr., Astarita G. Metabolomics and Lipidomics Reveal a Pro-Inflammatory Response to Ionizing Radiation. Metabolomics Society 2016 · Dublin, Ireland · June–July 2016.

Paglia G, Astarita G. An Unbiased Metabolomic Investigation of the Alzheimer's Disease Brain Points to a Dysregulation of Mitochondrial Aspartate Metabolism. HPLC 2016 · San Francisco · June 2016.

Laiakis EC, Strassburg K, ..., Fornace AJ Jr., Astarita G. PUFA-mediated proinflammatory response to ionizing radiation. 7th International Conference on Phospholipase A2 and Lipid Mediators · San Diego · May 2016.

Laiakis EC, Strassburg K, Bogumil R, Lai S, ..., Fornace AJ Jr., Astarita G. PUFA-mediated proinflammatory response to ionizing radiation. LipidMaps 2016 · San Diego · May 2016.

Ghaste M, Astarita G, Mattivi F, Shulaev V. Atmospheric pressure gas chromatography MS (APGC-MS) based metabolomics profiling of grape volatiles. 64th ASMS Conference · San Antonio · June 2016.

Pannkuk EL, Laiakis EC, Mak TD, Astarita G, Authier S, Wong K, Fornace AJ Jr. A lipidomic and metabolomic serum signature from nonhuman primates exposed to ionizing radiation. 62nd Annual Meeting of the Radiation Research Society · Hawaii · October 2016.

Astarita G, Kang J. Markers of Health: Molecular Phenotyping Unveils the Healthy Biosignature of "Omega-3" Transgenic Mice. Keystone Symposium: Human Nutrition, Environment and Health · Beijing · October 2015.

Paglia G, Pacini T, Gudmundsson S, ..., Palsson BO, Astarita G. Multidimensional analytical approaches combining ion mobility with MS-based metabolomics. CoSMoS · San Diego · August 2015.

Laiakis EC, Strassburg K, Bogumil R, ..., Fornace AJ Jr., Astarita G. Lipid Proinflammatory response to radiation exposure. 2nd Metabolomics – Bioactive Lipid Mediators · Budapest, Hungary · July 2015.

Laiakis EC, Strassburg K, Bogumil R, Lai S, ..., Fornace AJ Jr., Astarita G. Metabolic Phenotyping reveals a lipid-mediated proinflammatory response to radiation exposure. Metabolomics Conference 2015 · Burlingame, CA · June–July 2015.

Laiakis EC, Pannkuk EL, Chauthe SK, Wang YW, ..., Mak TD, Astarita G, Barker CA, Fornace AJ Jr. Comprehensive metabolomic analyses of serum from total body irradiated humans. 15th International Congress of Radiation Research · Kyoto, Japan · May 2015.

Lai S, Rainville P, Doneanu A, Johnson J, Murphy J, Plumb R, Astarita G. Targeted and Untargeted Lipidomics using Integrated Microfluidics Mass Spectrometry. 63rd ASMS Conference · St. Louis · May–June 2015.

Rainville P, Murphy J, Astarita G, Wilson I, Langridge J. Singulus Pulpitum: Microfluidics coupled with MS for Multi-omics and Targeted Assays. 63rd ASMS Conference · St. Louis · May–June 2015.

Paglia G, Pacini T, Gudmundsson S, Chiaravalle AE, Brynjolfsson S, Palsson BO, Astarita G. Multidimensional analytical approaches combining ion mobility with MS-based metabolomics. 63rd ASMS Conference · St. Louis · May–June 2015.

Laiakis EC, Strassburg K, Lai S, Vreeken RJ, Hankemeier T, Langridge J, Plumb R, Fornace AJ Jr., Astarita G. A MS-based metabolic phenotyping strategy to investigate the molecular response to ionizing radiation. 63rd ASMS Conference · St. Louis · May–June 2015.

Williams JP, Abdel-Khalik J, Wang Y, Stow SM, Towers M, Astarita G, Langridge J, Griffiths WJ. Analysis of Bile Acids with enhancement using Ion Mobility-TOFMS. 63rd ASMS Conference · St. Louis · May–June 2015.

Beecher C, de Jong F, Astarita G. Structural Elucidation of the Metabolome using IROA in combination with UHPLC-QTOF and DIA. 63rd ASMS Conference · St. Louis · May–June 2015.

Ghaste M, Astarita G, Mattivi F, Shulaev V. Enhanced metabolite profiling using APGC coupled with ion mobility MS. 63rd ASMS Conference · St. Louis · May–June 2015.

Thompson JW, DuBois L, Pratt B, MacCoss MJ, Astarita G, MacLean B, Moseley MA. Skyline Validation of Quantitative Measurements from High-Resolution LC-IMS-MS Lipidomics. 63rd ASMS Conference · St. Louis · May–June 2015.

Laiakis EC, Strassburg K, Bogumil R, Lai S, ..., Fornace AJ Jr., Astarita G. Characterization of a lipid-mediated inflammatory response to radiation exposure. 2nd Metabolomics: Advances & Applications in Human Disease · Cambridge, MA · May 2015.

Laiakis EC, Strassburg K, Lai S, Vreeken RJ, Hankemeier T, Plumb R, Fornace AJ Jr., Astarita G. A Lipid-mediated Proinflammatory Response to Ionizing Radiation. LipidMaps 2015 · San Diego · May 2015.

Kramer G, Dekker N, Gethings LA, Lee V, Astarita G, Beynon RJ, Langridge JI, Vissers JPC, Aerts JMFG. A data independent LC-MS multi-omic approach to investigate obesity treatment in a mouse model. MSACL 2015 · San Diego · March–April 2015.

Laiakis EC, Strassburg K, Bogumil R, Lai S, Vreeken RJ, Hankemeier T, Langridge J, Plumb RS, Fornace AJ Jr., Astarita G. Metabolic Phenotyping reveals a Lipid Mediator Response to Ionizing Radiation. MSACL 2015 · San Diego · March–April 2015.

Thompson JW, Pratt B, Horowitz-Gelb M, DuBois LG, St. John-Williams L, Astarita G, Moseley MA, MacCoss M, MacLean B. Skyline for small molecules: a flexible tool for LC-MS/MS method creation for metabolomics. MSACL 2015 · San Diego · March–April 2015.

Astarita G, McKenzie J, Langridge J, Kang J. Lipidomics of "Omega-3" Transgenic Mice Reveals a Panel of Anti-Inflammatory and Pro-Resolving Mediators. Brain and Lipids III, Journées CHEVREUL · Paris · March 2015.

Laiakis EC, Strassburg K, Lai S, Vreeken RJ, Hankemeier T, Langridge J, Plumb RS, Fornace AJ Jr., Astarita G. Metabolic Phenotyping reveals a Lipid Mediator Response to Ionizing Radiation. Keystone Symposium on Systems Biology and Lipids · Breckenridge, CO · February 2015.

Realini N, Avanesian A, Astarita G, Grimaldi B, Justinova Z, ..., Piomelli D. Methamphetamine accelerates cellular senescence through stimulation of de novo ceramide biosynthesis. Society for Neuroscience 2014 · Washington DC · November 2014.

Astarita G, Jones M, Doneanu A, Johnson J, Murphy J, Plumb R, Langridge J. Microfluidics Lipidomics Using a Novel Integrated Mass Spectrometry Technology. HPLC 2014 · New Orleans · May 2014.

Astarita G, Thompson W, Doneanu A, Cohen SA, Johnson J, Moseley A, Murphy J, Plumb R, Langridge J. A Flexible Platform for Lipidomics and Systems Biology. LipidMaps 2014 · San Diego · May 2014.

Paglia G, Angel P, Lai S, Walsh C, Langridge J, Plumb R, Astarita G. A unique brain lipidome and metabolome biosignature in Alzheimer's disease. AACC · Chicago · July 2014.

Isaac G, Astarita G, Lai S, Ladak A, Langridge JI, Shockcor J, Borthwick A. Use of Fragment Ion and CCS for Confident Identification from LC-IM-MS Metabolomics Data. 62nd ASMS Conference · Baltimore · June 2014.

Salazar C, Isaac G, Lai S, ..., Langridge JI, Mittler R, Astarita G, Shulaev V. Metabolomics Study of Arabidopsis Mutants Using APGC-MS^E and Multivariate Statistical Analysis. 62nd ASMS Conference · Baltimore · June 2014.

Paglia G, Williams JP, Menikarachchi L, Thompson JW, ..., Palsson BO, Astarita G. Ion Mobility-Derived Collision Cross-Sections Databases for Metabolomics and Lipidomics. 62nd ASMS Conference · Baltimore · June 2014.

Shulaev V, Ghaste M, Lai S, Salazar C, Suzuki N, Crossley J, Mittler R, Langridge JI, Astarita G, Mattivi F. Metabolomics Profiling using Atmospheric Pressure Gas Chromatography-MS. 62nd ASMS Conference · Baltimore · June 2014.

Lai S, Doneanu A, Murphy J, Langridge JI, Astarita G. Lipidomics of Alzheimer's Disease using an Integrated Microfluidic-Ion Mobility-MS Device. 62nd ASMS Conference · Baltimore · June 2014.

Astarita G, McKenzie J, Langridge J, Kang J. Lipidomics Profiling Unveils the Molecular Phenotype of "Omega-3" Transgenic Mice. International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases · San Juan, PR · November 2013.

Astarita G, Maldini M, Baima S, Natella F, Scaccini C, Langridge J. Metabolomics of broccoli sprouts using UPLC with ion mobility MS^E. 3rd MS Food Day · Trento, Italy · October 2013.

Thompson JW, Johnson J, Astarita G, Tang X, Paglia G, ..., Langridge J, Moseley MA. Multi-Omics Profiling of Methionine-Restricted MCF7 Cells Using a Prototype Microfluidic Device. 61st ASMS Conference · Minneapolis · June 2013.

Martin R, Strassburg K, Hankemeier T, Isaac G, Langridge J, Mallet C, Vreeken R, Astarita G. Rapid Profiling of Oxylipins for Drug Discovery, Nutritional and Clinical Research. 61st ASMS Conference · Minneapolis · June 2013.

Astarita G, Doneanu A, Thompson W, Cohen S, Isaac G, Johnson J, Moseley A, Murphy J, Langridge J. Lipidomic Profiling using a Prototype Microfluidic MS Platform. 61st ASMS Conference · Minneapolis · June 2013.

Paglia G, Astarita G, Thompson JW, Williams JP, Langridge J, Palsson BO. Collision-Cross Sections of Common Cellular Metabolites to support Metabolomics Applications. 61st ASMS Conference · Minneapolis · June 2013.

Astarita G, Maldini M, Baima S, Natella F, Scaccini C. Metabolomics of broccoli sprouts using UPLC with ion mobility MS^E. Massa 2012 · Palermo, Italy · June 2012.

Astarita G, Isaac G, Neeson KJ, Kirk J, Goshawk J, Shockcor J, Millar A, Langridge J. Complete fatty acid profiling using a single LC-MS based lipidomic approach. ISSFAL 2012 · Vancouver · May–June 2012.

Roehring C, Daxboeck M, Bogumil R, Astarita G, Langridge J, Cohen S, Langsdorf M. Quantitative Targeted Metabolomics Using a Combined Flow Injection LC-MS/MS Assay. 60th ASMS Conference · Vancouver · May 2012.

Doneanu A, Murphy J, Johnson J, Cohen SA, Astarita G, Chakraborty A. A New Separation Platform for High-Throughput Microscale Applications. 60th ASMS Conference · Vancouver · May 2012.

Krechmer J, Isaac G, Tice J, Neeson KJ, Millar A, Balogh MP, Langridge J, Astarita G. Real-time lipidomic profiling using desorption ionization with ion mobility separation. 60th ASMS Conference · Vancouver · May 2012.

Astarita G, Isaac G, Gorenstein MV, Shockcor JP, Ritchie M, Langridge J. Multi-dimensional lipidomics analysis using HILIC with ion mobility MS. 60th ASMS Conference · Vancouver · May 2012.

Lam TT, Isaac G, Giannini C, Yu K, Astarita G, ..., Langridge J, Herzog RI. Characterizing human insulin resistance via plasma metabolic profiling using ion mobility. 60th ASMS Conference · Vancouver · May 2012.

Isaac G, Cheema A, Neeson KJ, ..., Langridge J, Astarita G. Comprehensive fatty acid profiling using a single lipidomic approach. 60th ASMS Conference · Vancouver · May 2012.

Yokoi Y, Astarita G, Isaac G, Langridge J, Kikuchi N. Automated shotgun lipidomic analysis using LipidSearch with triple quad and ion mobility-TOF. 60th ASMS Conference · Vancouver · May 2012.

Claude E, Towers MW, Neeson KJ, Astarita G, Vissers JPC. Data independent MALDI Imaging ion mobility acquisition for lipid visualization from tissue. 60th ASMS Conference · Vancouver · May 2012.

Astarita G, Isaac G, Langridge J. Plant lipidomics using UPLC coupled to ion mobility MS. 11th Annual Oxford International Conference on the Science of Botanicals · Oxford, MS · April 2012.

Jones MD, Isaac G, Astarita G, Aubin A, Shockcor J, Legido-Quigley C, Smith N. A Sub-2μm Packed Column SFC-MS for Polar Lipid Analysis. Pittcon · Orlando, FL · March 2012.

Astarita G, Gorenstein MV, Isaac G, Shockcor JP, Ritchie M, Langridge J. Mapping lipidomes by coupling HILIC and ion mobility MS^E. International Singapore Lipid Symposium · Singapore · March 2012.

Astarita G, Isaac G, Shockcor JP, Langridge J. Lipidomic profiling using ultra performance LC Ion Mobility-TOF. International Society of Systems Biology 2012 · San Francisco · February 2012.

Astarita G, Isaac G, Shion H, McDonald S, Shockcor JP, Millar A, Langridge J. Lipidomic Screening for Biomarker Discovery using UPLC/Ion Mobility/MS^E. Clinical Applications MS · San Diego · January 2012.

Isaac G, Astarita G, Shion H, McDonald S, Shockcor JP, Millar A, Langridge J. A Novel Global Lipid Biomarker Workflow from a Complex Biological Sample. ASMS Asilomar Meeting on Metabolomics · Monterey · September–October 2011.

DiPatrizio NV, Astarita G, Li X, Schwartz GJ, Piomelli D. A peripheral endocannabinoid mechanism enhances dietary fat intake. Society for Neuroscience · San Diego · November 2010.

DiPatrizio NV, Astarita G, Shibuya A, Li X, Schwartz GJ, Piomelli D. Fat intake stimulates endocannabinoid mobilization in the small intestine through a cephalic mechanism. Society for the Study of Ingestive Behavior · Pittsburgh · July 2010.

Wang H, Taussig M, Astarita G, Piomelli D, Nave KA, Goldberg IJ, Eckel R. Abnormal brain lipid metabolism precedes obesity and dementia in neuron-specific LPL-deficient mice. Obesity Society 28th Annual Meeting · San Diego · October 2010.

Astarita G, Jung KM, Berchtold NC, Nguyen NQ, Gillen DL, Head E, Cotman CW, Piomelli D. Deficient liver biosynthesis of DHA correlates with cognitive impairment in Alzheimer's disease. ISSFAL 2010 · Maastricht, The Netherlands · May–June 2010.

Guerrera C, Astarita G, Colas J, Sands D, ..., Ollero M. Phospholipid signatures in plasma from CF patients associated with respiratory disease severity. 23rd North American Cystic Fibrosis Conference · Minneapolis · October 2009.

Fu J, Guijarro A, Gaetani S, Astarita G, Schwartz GJ, Piomelli D. Sympathetic system controls feeding-induced mobilization of NAPE and OEA. Society for the Study of Ingestive Behavior · Portland, OR · July–August 2009. Published in Appetite 52:833 (2009).

Guijarro A, Fu J, Astarita G, Piomelli D. CD36 deletion is associated with decreased OEA production in the mouse small intestine. Society for the Study of Ingestive Behavior · Portland, OR · July–August 2009. Published in Appetite 52:834 (2009).

Astarita G, Head E, Cotman CW, Piomelli D. Omega-3 fat deficit in Alzheimer's disease links cognitive impairment to liver metabolism. Alzheimer's Association International Conference · Vienna · July 2009.

Ahmed F, Astarita G, Xiao H, Piomelli D. Application of HPLC-Chip/MS to the study of rat brain lipidomics. HPLC-2009 · Dresden, Germany · June 2009.

Guerrera C, Colas J, Sands D, ..., Astarita G, Piomelli D, Edelman A, Ollero M. Revealing potential plasma lipid biomarkers of cystic fibrosis by MS. 32nd European Cystic Fibrosis Conference · Brest, France · June 2009.

Jung KM, Astarita G, Yasar S, Head E, Cotman CW, Piomelli D. Deficits in anandamide signaling underlies cognitive dysfunction in Alzheimer's disease. Society for Neuroscience 38th Annual Meeting · Washington DC · November 2008.

Di Sabatino A, ..., Astarita G, Piomelli D, Maccarrone M, Corazza GR. A key role for gut endocannabinoid system in IBD. 109° Congresso Nazionale SIMI · Genoa, Italy · October 2008.

Di Sabatino A, ..., Astarita G, Piomelli D, Maccarrone M, Corazza GR. A key role for gut cannabinoid receptors in IBD. 16th United European Gastroenterology Week · Vienna · October 2008.

Di Sabatino A, ..., Astarita G, Piomelli D, Maccarrone M, Corazza GR. Mucosal endocannabinoid system in IBD. 6th European Mucosal Immunology Group Meeting · Milan · October 2008.

Astarita G, Piomelli D. LC/MS analysis of diacylglycerol lipase-mediated lipid metabolism in neural cells. 57th ASMS Conference on Mass Spectrometry · Denver · May–June 2008.

Ahmed F, Astarita G, Xiao H, Piomelli D. Mapping of Lipid Profiles of Rat Brain Regions by LC-MS. 32nd International Symposium on Capillary Chromatography & GCxGC · Riva del Garda, Italy · May–June 2008.

Ahmed F, Astarita G, Xiao H, Geaga J, Clapper J, Piomelli D. Mapping of Lipid Profiles of Rat Brain Regions by LC-MS. 32nd HPLC Symposium · Baltimore · May 2008.

Di Sabatino A, Battista N, Biancheri P, ..., Astarita G, Piomelli D, Maccarrone M, Corazza GR. A key role for the endocannabinoid system in IBD. XIV Congresso Nazionale delle Malattie Digestive · Rimini, Italy · March 2008.

Jung KM, Astarita G, Zhu C, Wallace M, Katona I, Freund TF, Mackie K, Piomelli D. A key role for diacylglycerol lipase-α in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Society for Neuroscience 37th Annual Meeting · San Diego · November 2007.

Astarita G, Ahmed F, Piomelli D. Identification of N-acylphosphatidylethanolamines precursors for anandamide in the rat brain. Neuropharmacology Cannabinoid Symposium · San Diego · October 2007.

Azzara AV, Li XS, Fu J, Astarita G, et al. Extrinsic neural controls of food-stimulated intestinal OEA release. Society for Neuroscience 36th Annual Meeting · Atlanta · October 2006.

Fu J, Kim J, Astarita G, Phan P, Piomelli D. Endocannabinoid levels are regulated by a novel phospholipase D in rat brain culture. IUPHAR 15th World Congress of Pharmacology · Beijing · July 2006.